DUPONT MERCK Tc-99m MARKER IS 90% ACCURATE IN DETECTING BREAST CANCER, STUDY SHOWS; SEPARATE TRIAL SUPPORTS ULTRASOUND AS ADJUNCT TO MAMMOGRAPHY
This article was originally published in The Gray Sheet
Executive Summary
Scintimammography performed with Dupont Merck's technecium-99m sestamibi nuclear marker can correctly identify more than 90% of cancers in women with "suspicious" tissue masses, Iraj Khalkhali, MD, University of California, Los Angeles, reported in a Nov. 28 press conference at the Radiological Society of North America's annual meeting in Chicago.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.